Skip to main content

Table 2 Median densities of various immune marker–expressing cells in NSCLCs from patients who received neoadjuvant chemotherapy (NCT) or did not receive NCT (non-NCT) (N = 112)

From: Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

Markers non-NCT (n = 61) NCT (n = 51) P a
Median Cell Density (cells/mm2)  
Panel 1
 MCs (AE1/AE3+) 3559.79 3269.35 0.615
 MCs PD-L1+ 34.37 574.58 0.022
 CD3+ 903.21 1501.99 0.021
 CD3 + CD4+ 671.00 1031.88 0.040
 CD3 + CD8+ 156.38 276.08 0.588
 CD68+ 298.80 609.36 0.059
 CD68 + PD-L1+ 194.46 307.32 0.122
Panel 2
 MCs (AE1/AE3+) 3536.02 2970.70 0.157
 CD45RO+ 668.75 1180.26 0.290
 CD45RO + CD57 + granzyme B− 679.09 965.58 0.147
 CD45RO + PD-1+ 153.73 443.04 < 0.001
 CD45RO + FOXP3+ 5.38 8.37 0.427
 CD57 + granzymeB+ 6.87 20.32 < 0.001
 PD-1+ 336.02 795.21 < 0.001
  1. MC malignant cells
  2. aMann Whitney U test